Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

131.89 +1.17 (+0.90%)
Streaming Delayed Price Updated: 2:08 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,057,296
Open 130.13
Bid (Size) 131.89 (5)
Ask (Size) 131.91 (2)
Prev. Close 130.72
Today's Range 130.13 - 131.90
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.21%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
+16.47%
+16.47%
1 Month
+5.08%
+5.08%
3 Month
+9.79%
+9.79%
6 Month
+24.96%
+24.96%
1 Year
+16.28%
+16.28%

More News

Read More
Merck (MRK) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
3 Under-The-Radar Stocks With Positive Potential
Via Talk Markets
Unveiling 17 Analyst Insights On Merck & Co
Via Benzinga
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Via Benzinga
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
Via Benzinga
Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist
Via Investor's Business Daily
Merck Announces First-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Via Benzinga
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Investor Alert: Prepare for the Market Crash With These 3 Stocks
Via InvestorPlace
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
Via InvestorPlace
Topics Stocks
Exposures US Equities
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.